Last reviewed · How we verify
Vaxchora
At a glance
| Generic name | Vaxchora |
|---|---|
| Also known as | CVD 103-HgR |
| Sponsor | University of Maryland, Baltimore |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya (PHASE4)
- Immunologic Responses to a Live Attenuated Oral Cholera Vaccine (PHASE2)
- A Post-marketing Observational Study of Oral Cholera Vaccine (PHASE4)
- Vaccine- and Infection-derived Correlates of Protection for Cholera. (NA)
- Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus (PHASE3)
- Safety and Immunogenicity Study of the DuoChol Oral Cholera Vaccine in Healthy Participants (PHASE1)
- Phase 1b Ascending Dose Study of PanChol in Healthy Volunteers (PHASE1)
- CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaxchora CI brief — competitive landscape report
- Vaxchora updates RSS · CI watch RSS
- University of Maryland, Baltimore portfolio CI